Evangelos Giamarellos-Bourboulis: Phase 3 SAVE-MORE Study Results Investigating Anakinra in the Treatment of Severe COVID-19

It was a great pleasure to meet with Prof. Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Athens, Greece) to discuss phase 3 SAVE-MORE study assessing the effect of anakinra for the treatment of patients with COVID-19 pneumonia.

Useful Resources:

Publication available to access here: https://www.nature.com/articles/s41591-021-01499-z

Questions:

1. Could you give us a brief overview of the role of the IL-1 pathways in the pathogenesis of COVID-19? (0:17)
2. Following the results for canakinumab in COVID-19, what was the rationale for investigating anakinra in the treatment of severe COVID-19? (1:47)
3. What were the aims and design of the SAVE-MORE study? (3:47)
4. What were the findings of the study? (5:01)
5. Based on these findings, where do you see anakinra sitting in the treatment paradigm for COVID-19 and which patients are most likely to benefit from its use? (6:46)

Disclosures: Evangelos Giamarellos-Bourboulis has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.